Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating × efgartigimod alfa × 1 year × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Myasthenia Gravis 5 Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 1

Interventions

thymoglobulin 1 prednylidene 1 fludarabine 1 efgartigimod alfa 1 deltacortene 1 carmustine, poliferprosan 20 drug combination 1 Prednisone 1 Physical Therapy Modalities 1 Peripheral Blood Stem Cell Transplantation 1 Melphalan 1 Etoposide 1 Cytarabine 1 Cyclophosphamide 1 Carmustine 1 Antilymphocyte Serum 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06299748 2026-02-17

A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.

argenx

Myasthenia Gravis, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Data powered by HemOnc (CC BY 4.0) Colophon ⚡